PROM1 and lung cancer: Trifluoperazine treatment of lung cancer stem cells reduced the sphere-forming ability of lung cancer cells and down-regulated CD44 and CD133 expression, and trifluoperazine in combination with gefitinib or cisplatin effectively controlled drug resistance in lung cancer cells [39].